Journal List > Endocrinol Metab > v.27(1) > 1085978

TOOLS
Kim, Park, Yu, Kang, Ryu, Lee, Hong, Kim, Yoo, Ihm, Choi, and Yoo: Impact of Serum Adiponectin Concentration on Progression of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus
Original Article
Endocrinology and Metabolism

Endocrinology and Metabolism 2012; 27(1): 31-38.

Published online: 21 March 2012

DOI: https://doi.org/10.3803/EnM.2012.27.1.31

Impact of Serum Adiponectin Concentration on Progression of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus

Chul Sik Kim, Ju Ri Park, Sung Hoon Yu, Jun Goo Kang, Ohk Hyun Ryu, Seong Jin Lee, Eun Gyung Hong, Doo-Man Kim, Jae Myung Yoo, Sung Hee Ihm, Moon Gi Choi, Hyung Joon Yoo

Division of Endocrinology, Department of Internal Medicine, Hallym University College of Medicine, Anyang, Korea.

Corresponding author: Chul Sik Kim. Division of Endocrinology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, 22 Gwanpyeong-ro 170 beon-gil, Dongan-gu, Anyang 431-796, Korea. Tel: +82-31-380-6061, Fax: +82-31-380-2269, ironeat@gmail.com

Received 26 July 2011       Accepted 14 December 2011

Copyright © 2012 Korean Endocrine Society

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Increased cardiovascular events, which is the leading cause of death in type 2 diabetic patients, are mainly caused by accelerated atherosclerosis. Adiponectin has been suggested as a risk factor for cardiovascular diseases in cross-sectional studies. However, little is known about the impact of adiponectin on the progression of carotid atherosclerosis in type 2 diabetic patients. This study was conducted to evaluate the impact of early adiponectin levels on the progression of carotid atherosclerosis.

Methods

From March 2009, 150 patients with type 2 diabetes were consecutively enrolled in our affiliated outpatient clinic. Anthropometric and biochemical data, including adiponectin levels, were measured in each participant. We measured the carotid intima-media thickness (CIMT) at baseline and at 1-year follow-up (n = 111). Then, we prospectively studied the relationship between the serum adiponectin levels and the progression of CIMT for 1 year.

Results

Adiponectin levels negatively correlated with CIMT (r = -0.219, P = 0.015). Moreover, mean progression of CIMT was 0.016 ± 0.040 mm. However, there was no correlation between adiponectin levels and the progression of CIMT within 1-year follow-up period (r = -0.156, P = 0.080). Age (β = 0.556, P = 0.004), LDL cholesterol (β = 0.276, P = 0.042), and A1C (β = 0.309, P = 0.038) were found to be independent risk factors for CIMT. However, A1C (β = 0.311, P = 0.042) was found to be the only independent risk factor for the progression of CIMT.

Conclusion

In our study, adiponectin levels were negatively associated with CIMT. However, it did not affect the progression of CIMT at 1-year follow-up. Overall glycemic control is the most important factor in the progression of CIMT in patients with type 2 diabetes.

Keywords: Adiponectin, Carotid atherosclerosis, Carotid intima media thickness, Type 2 diabetes mellitus

Figures and Tables

Fig. 1
Correlation between serum adiponectin concentration (log transformed) and baseline carotid artery intima-media thickness (CIMT). (r = -0.219, P = 0.015).
enm-27-31-g001
Fig. 2
Correlation between serum adiponectin concentration (log transformed) and progression of carotid artery intima-media thickness (CIMT) (r = -0.156, P = 0.080).
enm-27-31-g002
Table 1
Clinical and biochemical characteristics of the subjects according to progression of carotid intima-media thickness
enm-27-31-i001

Values are expressed as mean ± SD.

CIMT, carotid intima-media thickness; DPP4, dipeptidyl peptidase-4; HDL, high density lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; LDL, low-density lipoprotein; Ln, lymph node; RAS, renin angiotensin system.

Table 2
Differences in medication use in 1 year
enm-27-31-i002

Values are expressed as %.

DPP4, dipeptidyl peptidase- 4; RAS, renin angiotensin system.

Table 3
Multivariate logistic regression modeling for predictors of carotid artery intima-media thickness in type 2 diabetic patients
enm-27-31-i003

BMI, body mass index; HDL-C, high density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment for insulin resistance; LDL-C, low density lipoprotein cholesterol; Ln, lymph node.

Table 4
Multivariate logistic regression modeling for predictors of progression of carotid artery intima-media thickness in type 2 diabetic patients
enm-27-31-i004

BMI, body mass index; CIMT, carotid artery intima-media thickness; HDL-C, high density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment for insulin resistance; LDL-C, low density lipoprotein cholesterol; Ln, lymph node.

References

1. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999. 159:1104–1109.
2. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev. 1997. 5:294–315.
3. Hu Y, Liu W, Huang R, Zhang X. Postchallenge plasma glucose excursions, carotid intima-media thickness, and risk factors for atherosclerosis in Chinese population with type 2 diabetes. Atherosclerosis. 2010. 210:302–306.
4. Ho HC, Chen MF, Hwang JJ, Lee YT, Su TC. Intima-media thickness of lower-limb arteries associated with fasting and post-challenge plasma glucose levels. J Atheroscler Thromb. 2009. 16:748–755.
5. Yokoyama H, Katakami N, Yamasaki Y. Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke. 2006. 37:2420–2427.
6. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998. 128:262–269.
7. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C, Pfutzner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation. 2005. 111:2525–2531.
8. Katakami N, Yamasaki Y, Hayaishi-Okano R, Ohtoshi K, Kaneto H, Matsuhisa M, Kosugi K, Hori M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004. 47:1906–1913.
9. Fateh-Moghadam S, Li Z, Ersel S, Reuter T, Htun P, Plockinger U, Bocksch W, Dietz R, Gawaz M. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler Thromb Vasc Biol. 2005. 25:1299–1303.
10. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996. 221:286–289.
11. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001. 7:941–946.
12. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999. 257:79–83.
13. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001. 86:1930–1935.
14. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y. Osaka CAD Study Group. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003. 23:85–89.
15. Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG, Kim NH, Choi DS, Baik SH. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf). 2004. 61:75–80.
16. Lim S, Jang HC. Clinical implication of adiponectin. Korean Diabetes J. 2008. 32:85–97.
17. Pilz S, Horejsi R, Möller R, Almer G, Scharnagl H, Stojakovic T, Dimitrova R, Weihrauch G, Borkenstein M, Maerz W, Schauenstein K, Mangge H. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J Clin Endocrinol Metab. 2005. 90:4792–4796.
18. Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study. Stroke. 2005. 36:2577–2582.
19. Nilsson PM, Engström G, Hedblad B, Frystyk J, Persson MM, Berglund G, Flyvbjerg A. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol. 2006. 26:2758–2762.
20. World Health Organization. WHO Expert Committee on Diabetes Mellitus. 1980. 2nd Report. Geneva: World Health Organization.
21. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987. 3:463–524.
22. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979. 241:2035–2038.
23. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985. 110:1100–1107.
24. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004. 291:1730–1737.
25. Lim S, Koo BK, Cho SW, Kihara S, Funahashi T, Cho YM, Kim SY, Lee HK, Shimomura I, Park KS. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis. 2008. 196:398–404.
26. Handa N, Matsumoto M, Maeda H, Hougaku H, Ogawa S, Fukunaga R, Yoneda S, Kimura K, Kamada T. Ultrasonic evaluation of early carotid atherosclerosis. Stroke. 1990. 21:1567–1572.
27. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, Rosamond WD, Evans G. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2000. 151:478–487.
28. Allan PL, Mowbray PI, Lee AJ, Fowkes FG. Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study. Stroke. 1997. 28:348–353.
29. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007. 115:459–467.
30. Johnson HM, Douglas PS, Srinivasan SR, Bond MG, Tang R, Li S, Chen W, Berenson GS, Stein JH. Predictors of carotid intima-media thickness progression in young adults: the Bogalusa Heart Study. Stroke. 2007. 38:900–905.
31. Hodis HN, Mack WJ. Risk factor assessment, treatment strategy and prevention of coronary artery disease: the need for a more rational approach. J Intern Med. 1994. 236:111–113.
32. Chambless LE, Folsom AR, Davis V, Sharrett R, Heiss G, Sorlie P, Szklo M, Howard G, Evans GW. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol. 2002. 155:38–47.
33. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond). 2006. 110:267–278.
34. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007. 13:332–339.
35. Juonala M, Saarikoski LA, Viikari JS, Oikonen M, Lehtimäki T, Lyytikäinen LP, Huupponen R, Magnussen CG, Koskinen J, Laitinen T, Taittonen L, Kähönen M, Kivimäki M, Raitakari OT. A longitudinal analysis on associations of adiponectin levels with metabolic syndrome and carotid artery intima-media thickness. The Cardiovascular Risk in Young Finns Study. Atherosclerosis. 2011. 217:234–239.
36. Tsushima M, Terayama Y, Momose A, Funyu T, Ohyama C. Progression of atherosclerosis in hemodialysis patients: effect of adiponectin on carotid intima media thickness. J Atheroscler Thromb. 2008. 15:213–218.
37. Nguyen QM, Toprak A, Xu JH, Srinivasan SR, Chen W, Berenson GS. Progression of segment-specific carotid artery intima-media thickness in young adults (from the Bogalusa Heart Study). Am J Cardiol. 2011. 107:114–119.
38. Stork S, Bots ML, Angerer P, von Schacky C, Grobbee DE, Angermann CE, Seufert J. Low levels of adiponectin predict worsening of arterial morphology and function. Atherosclerosis. 2007. 194:e147–e153.
39. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem. 2003. 278:9073–9085.
TOOLS
Similar articles